Loading...
•
Jun 30
Assertio Q2 2025 Earnings Report
Assertio's Q2 2025 financial results were reported, showing continued progress in executing its 2025 transformation priorities, with increased cash and investments, and narrowed full-year guidance.
Key Takeaways
Assertio Holdings, Inc. reported its second quarter 2025 financial results, demonstrating continued progress in its transformation strategy. The company saw an increase in cash and investments to over $98 million, driven by strong Adjusted EBITDA performance and favorable working capital. Net product sales were $28.8 million, with key growth assets like Rolvedon and Sympazan performing well, while Indocin sales decreased due to generic competition. The company also streamlined operations, divested Assertio Therapeutics, and ceased commercialization of Otrexup to optimize its cost structure.
Total net product sales for Q2 2025 were $28.8 million, a decrease from $30.7 million in the prior year quarter.
Cash, cash equivalents, and short-term investments increased to $98.2 million as of June 30, 2025, up from $87.3 million as of March 31, 2025.
Adjusted EBITDA for the second quarter was $5.6 million, an increase from $3.1 million in the prior year quarter.
The company narrowed its full-year guidance for Net Product Sales to $108.0 million to $118.0 million and for Adjusted EBITDA to $11.0 million to $19.0 million.
Assertio
Assertio
Assertio Revenue by Segment
Revenue by Segment
Net Product Sales Revenue
CapyFin.comRoyalty Revenue
CapyFin.comRolvedon Net Product Sales Revenue
CapyFin.comSympazan Net Product Sales Revenue
CapyFin.comIndocin Net Product Sales Revenue
CapyFin.com Forward Guidance
Assertio narrowed its full-year guidance for Net Product Sales and Adjusted EBITDA, reflecting first-half performance, the decision to cease commercialization of Otrexup, and improved operational efficiencies.
Positive Outlook
- Full-year Net Product Sales guidance narrowed to $108.0 Million to $118.0 Million (previously $108.0 Million to $123.0 Million).
- Full-year Adjusted EBITDA guidance narrowed to $11.0 Million to $19.0 Million (previously $10.0 Million to $19.0 Million).
- Results through the second quarter are tracking well with full-year guidance.
- Enhancing growth and profit potential by focusing investment on core assets.
- Generating cash to support new growth drivers.
Challenges Ahead
- The decision to cease commercialization of Otrexup will impact future sales.
- Generic competition continues to affect products like Indocin.
- The divestiture of Assertio Therapeutics resulted in an $8.2 million loss.
- Operating expenses include one-time costs associated with the divestiture and decommercialization of Otrexup.
- Net product sales for the quarter decreased compared to the prior year.